Home rare diseases

Keyword: rare diseases

6 results found

Amid plans by the federal government to introduce national dental and pharmacare programs, key stakeholders in the private payer health-care sector should highlight the value of private health plans in Canada, according to a panel during a webinar by the Group Insurance Pharmaceutical Committee last week. In March, the Liberal Party and the New Democratic […]

Copyright_Aleksandr Kalugin_123RF

In 2020, Canada Life Assurance Co. saw a decrease in the number of benefits plan members making a drug claim, though the costs of those claims were higher, according to Barb Martinez, the insurer’s national practice leader in drug solutions, speaking during a session at Benefits Canada‘s Face to Face in Drug Plan Management Forum […]

In 2020, members of the Canadian Life and Health Insurance Association spent $650 million on drugs for rare diseases for more than 13,000 patients. Rare diseases affect one in 12 Canadians and between 6,000 and 8,000 rare diseases are known globally. In addition, roughly 80 per cent of these diseases occur in children and only […]

The Canadian Drug Insurance Pooling Corp.’s high-cost drug framework provided coverage to almost 28,000 Canadians and their families where drug costs exceeded $10,000 annually in 2020. According to its results, the CDIPC estimated that its member insurance companies reimbursed claims associated with 54 new high-cost drugs including those for rare diseases. As well, based on past experience, […]

  • By: Staff
  • December 22, 2021 December 21, 2021
  • 09:00

The proposed amendments to the patented medicines regulations by the Patented Medicine Prices Review Board could have a big impact on both the group insurance and pharmaceutical industry. “The CLHIA is very supportive of PMPRB adjustments that may be coming,” said Joan Weir, director of health and disability policy at the Canadian Life and Health […]

Copyright_Wavebreak Media Ltd_123RF

Discussion around implementing a national universal pharmacare strategy is growing louder ahead of next month’s federal election. In its 2019 budget, the federal government said it would work with partners to move forward on a national pharmacare program, including the creation of a new national drug agency and formulary, as well as a national strategy for […]